B of A Securities Maintains Neutral on Axsome Therapeutics, Lowers Price Target to $95
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has maintained a Neutral rating on Axsome Therapeutics (NASDAQ:AXSM) but has lowered the price target from $97 to $95.

July 18, 2024 | 4:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
B of A Securities has maintained a Neutral rating on Axsome Therapeutics but has lowered the price target from $97 to $95.
The Neutral rating suggests that the analyst does not expect significant short-term movement in the stock price. The slight reduction in the price target from $97 to $95 indicates a minor adjustment in expectations, which is unlikely to cause a major impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100